The National Institute for Health and Care Excellence (NICE) has recommended the use of four out of six disease-modifying therapies in relapsing–remitting multiple sclerosis.
In one of the largest studies of its kind, researchers have revealed that long-term use of some anticholinergics could be associated with an increased risk of dementia.
The UK DRI’s COO, Adrian Ivinson, discusses the UK DRI and the current dementia care research landscape, as well as new opportunities for dementia researchers to join the Institute.
Understanding important issues in young-onset dementia care: the perspective of healthcare professionals
Discover the clinical approaches towards young-onset dementia currently being employed by healthcare professionals and how these may be improved upon in this article from Neurodegenerative Disease Management.
Discover more about how advances in amyotrophic lateral sclerosis research are influencing approaches to patient care in this review from Neurodegenerative Disease Management
Stroke Administrative Severity Index: using administrative data for 30-day poststroke outcomes prediction
In this research article from Journal of Comparative Effectiveness Research find out more about a newly proposed stroke severity scale to improve patient care and rehabilitation.
New guidance from the International Society for Magnetic Resonance in Medicine provides recommendations for the use of gadolinium in imaging procedures.
This study aimed to assess the attitudes and opinions of clinicians practicing in psychiatry toward pharmacogenomic testing, and in so doing elicits possible barriers and risks to employ this technology in patient care.
This article examines a number of different disease-modifying therapy strategies for the treatment of relapsing-remitting multiple sclerosis.
In celebration of International Women’s Day, we spoke to Twyila about her accomplished career, gender challenges in nursing, and finding that elusive work–life balance.